Diabetic vascular injury and ACE: Potential for pharmacological prevention of complications of later life

Drugs and Aging

Volumn 8, Issue 1, 1996, Pages 38-46

  Cooper, Mark E ^a   Vranes, Dimitria ^a   Rumble, Jonathan R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; BRADYKININ; CALCIUM ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; INSULIN; KININ; METOPROLOL; VERAPAMIL;

ANIMAL MODEL; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0030052728     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199608010-00007     Document Type: Review

References (90)

1. Clark Jr CM, Lee DA. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 1995; 332: 1210-7
2. Valsania P, Zarich SW, Kowalchuk GJ, et al. Severity of coronary artery disease in young patients with insulin-dependent diabetes melliuis. Am Heart J 1991; 122: 695-700
3. Held PJ, Port FK, Biagg CR, et al. United States Renal Data System 1990 annual report. Am J Kidney Dis 1990; Suppl. 2: 1-106
4. Klein R, Klein BE, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care 1992; 15: 1875-91
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329: 977-86
6. Gilbert R, Tsalamandris C, Bach LA, et al. Longterm glycemic control and the rate of progression of early diabetic kidney disease. Kidney Int 1993; 44: 855-9
7. Natarajan R. Vascular smooth muscle cells exhibit increased growth in response to elevated glucose. Bioch Biophys Res Comm 1992; 187: 552-60
8. Alipui C, Ramos K, Tenner Jr T. Alterations of rabbit aortic smooth muscle cell proliferation in diabetes mellitus. Cardiovas Res 1993; 27: 1229-32
9. Lee TS, Saltsman KA, Ohashi H, et al. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci USA 1989; 86: 5141-5
10. Brownlee MA, Ceraini A, Vlassara H. Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988; 318: 131-8
11. Soulis-Liparota T, Cooper M, Papazoglou D, et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40: 1328-34
12. Hammes H-P, Strödter D, Weiss A. et al. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 1995; 38 (6): 656-60
13. Erdos EG. Conversion of angiotensin I to angiotensin II. Ann Rev Med 1976; 60: 749-59
14. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992; 90: 456-61
15. Tigerstedt R, Bergman P. Niere und Kreislauf. Scand Arch Physiol 1898; 8: 223-71
16. Dzau VJ. Vascular renin-angiolensin system and vascular protection. J Cardiovase Pharmacol 1993; 22: S1-S9
17. Kato H, Suzuki S, Tajima S, et al. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens 1991; 9: 17-22
18. Østerby R. Renal pathology in diabetes mellitus. Curr Opin Nephrol Hypertens 1993; 2: 475-83
19. Morishita R, Gibbons GH, Ellison KE, et al. Evidence for direct local effect of angiotensin in vascular hypertrophy. J Clin Invest 1994; 94: 978-84
20. Hirose K, Østerby R, Nozawa M. et al. Development of glomerular lesions in experimental long-term diabetes in the rat. Kidney Int 1982; 21: 689-95
21. Danser AH, Derkx FH, Admiraal PJ, et al. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994; 35: 1008-18
22. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265: F477-H6
23. Fernandez LA, Twickler J, Mead A. Neovascularisation produced by angiotensin II. J Lab Clin Med 1985; 105: 141-5
24. Vranes, D, Dilley RJ, Cooper ME. Vascular changes in the diabetic kidney: effects of ACE Inhibition. J Diabet Complications. In press
25. Cooper ME, Rumble J, Komers R, et al. Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin converting enzyme inhibition. Diabetes 1994; 43: 1221-8
26. Rumble JR, Doyle AE, Cooper ME. Comparison of effects of ACE inhibition with calcium channel blockade on renal disease in a model combining genetic hypertension with diabetes. Am J Hypertens 1995; 8: 53-7
27. Vranes D, Cooper ME, Dilley RJ. Angiotensin converting enzyme inhibition reduces diabetes-induced vascular hypertrophy: morphometric studies. J Vasc Res 1995; 32: 183-9
28. Rakugi H, Kim D-K, Krieger JE, et al. Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J Clin Invest 1994; 93: 339-46
29. Clozel JP, Kuhn H, Hefti F. Effects of chronic ACE inhibition on cardiac hypertrophy and coronary vascular reserve in spontaneously hypertensive rats with developed hypertension. J Hypertens 1989; 7: 267-75
30. Powell JS, Clozel J-P, Muller RKM, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186-8
31. Ignarro LJ, Buga GM, Chaudhuri G. EDRF generation and release from perfused bovine pulmonary artery and vein. Eur J Pharmacol 1990; 149: 79-88
32. Bao G, Gohlke P, Quadri F, et al. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 1992; 20: 74-9
33. Komers R, Cooper ME. Acute renal hemodynamic effects of angiotensin converting enzyme inhibitors in diabetic hyperfiltration: the role of kinins. Am J Physiol 1995; 37: F588-94
34. Rhaleb NE, Yang XP, Scicli AG, et al. Role of kinins and nitric oxide in the antihypertrophic effect of ramipril. Hypertension 1994; 23: 865-8
35. Farhy RD, Carretero OA, Ho K-L, et al. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993; 72: 1202-10
36. Rumble J, Komers R, Cooper M. Bradykin/nitric oxide is involved in the antihypertensive effects of ACE inhibitors on the mesenteric microvessels of the diabetic rat. Diabetologia 1994; 37(Suppl. 1) A71:275
37. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1994; 342: 821-8
38. Dahlof B, Pennert K, Hansson L. Reversal of LVH in hypertensive patients. A metanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110
39. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardiac infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77
40. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-8
41. DeFronzo RA, Ferranini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94
42. Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria on relative mortality in Type I (insulin-dependent) diabetes mellitus. Diabetologia 1985; 28: 590-6
43. Messent JW, Elliott TG, Hill RD, et al. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int 1992; 41: 836-9
44. Aberg G, Ferrer P. Effects of captoril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 15: S65-72
45. Fennessy PA, Campbell JH, Campbell GR. Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture. Atherosclerosis 1994; 106: 29-41
46. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993-2000
47. Zatz R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77: 1925-30
48. Cooper ME, Allen TJ, Macmillan PA, et al. Enalapril retards albuminuria and glomerular basement membrane thickening in experimental diabetic nephropathy. Diabetologia 1989; 32: 326-8
49. Cooper ME, Allen TJ, O'Brien RC, et al. Nephropathy in a model combining genetic hypertension with experimental diabetes: enalapril versus hydralazine and metoprolol therapy. Diabetes 1990; 39: 1575-9
50. Anderson S, Rennke HG, Brenner BM. Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int 1992; 41: 891-7
51. Brown SA, Walton CL, Crawford P, et al. Long term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993; 43: 1210-8
52. Harris DCH, Hammond WS, Burke TJ, et al. Verapamil protects against progression of experimental chronic renal failure. Kidney Int 1987; 31: 41-6
53. Yoshida Y, Kawamura T, Ikoma M, et al. Effects of antihypertensive drugs on glomerular morphology. Kidney Int 1989; 36: 626-35
54. Mogensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease: with emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983; 32: 64-78
55. Gilbert R, Cooper ME, McNally PG, et al. Microalbuminuria: prognostic and therapeutic implications in diabetes mellitus. Diabet Med 1994; 11: 636-45
56. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129-38
57. Solini A, DeFronzo RA. Hypertension, cardiovascular disease, diabetes mellitus, and diabetic nephropathy: role of insulin resistance. In: Mogensen CE, editor. The kidney and hypertension in diabetes mellitus. Norwell, Massachusetts: Kluwer Academic Publishers, 1994: 37-51
58. Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982; 285: 685-8
59. Parving HH, Anderson AR, Smidt UM, et al. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983; 1: 1175-9
60. Björk S, Nyberg G, Mulec H, et al. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 1986; 293: 467-70
61. Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 1988; 297: 1086-91
62. Parving H-H, Hommel E, Nielsen MD, et al. Effect of captopril on blood pressure and kidney function in normotensive insulin-dependent diabetics with nephropathy. BMJ 1989; 299: 533-6
63. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
64. Christensen CK, Mogensen CE. Effect of antihypertensive treatment on progression of incipient diabetic nephropathy. Hypertension 1985; 7 Suppl. II: 109-13
65. Marre M, Chatellier G, Leblanc H, et al. Prevention of diabetic nephropathy with cnalapril in normotensive diabetics with microalbuminuria. BMJ 1988; 297: 1092-5
66. Hallab M, Gallois Y, Chatellier G, et al. Comparison of reduction in microalbuminuria by cnalapril and hydrochlorothiazidein normotensive patients with insulin dependent diabetes. BMJ 1993; 306: 175-82
67. Mathiesen ER, Hommel E, Giese J, et al. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991; 303: 81-7
68. Viberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulindependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271: 275-9
69. Jerums G, Allen T, Tsalamandris C, et al. Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. Kidney Int 1992; 41: 904-11
70. Stornello M, Valvo EV, Scapellato L. Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovas Pharmacol 1989; 14: 851-5
71. Stornello M, Valvo EV, Scapellato L. Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria. Nephron 1991; 58: 52-7
72. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 112: 707-8
73. Slataper R, Vicknair N, Sadler R, et al. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993; 153: 973-80
74. Demarie BK, Bakris GI. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 113: 987-8
75. McNally PG, Cooper ME. Antihypertensive treatment in NIDDM, with special reference to abnormal albuminuria. In: Mogensen CE, editor. The kidney and hypertension in diabetes mellitus. Boston: Kluwer Academic, 1994: 341-52
76. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine and normotensive diabetic patients with microalbuminuria. BMJ 1991; 301: 210-6
77. Melbourne Diabetic Nephropathy Study Group. Effects of different antihypertensive agents on normotensive mirroalbuminuric Type I and Type II diabetic patients. Proceeedings of the XIIth International Congress of Nephrology: 1993 Jun 13-18; Jerusalem, 424
78. Lacourciere Y, Nadeau A, Poirier L, et al. Captopril or conventional therapy in hypertensive type II diabetics. Three year analysis. Hypertension 1993; 21: 786-94
79. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-81
80. Gambardella S, Frontoni S, Felici MG, et al. Efficacy of antihypertensive treatment with indapamide in patients with noninsulin dependent diabetes and persistent microalbuminuria. Am J Cardiol 1990; 65: 46H-50H
81. Jarret RJ, Viberti GC, Argyropouulos A, et al. Microalbuminuria predicts mortality in non-insulin dependent diabetes. Diabet Med 1984; 1: 17-9
82. Mogensen CE. Microalbuminuna predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-60
83. Damsgaard EM, Frøland A, Jørgensen OD, et al. Eight to nine year mortality in known non-insulin dependent diabetics and controls. Kidney Int 1992; 41: 731-5
84. The National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension and diabetes. Hypertension 1994; 23: 145-58
85. Consensus Panel. The management of hypertension: a consensus statement. Med J Aust 1994; 160 Suppl.: S1-S16
86. Consensus Statement. Treatment of hypertension in diabetes. Diabetes Care 1993; 16: 139-41
87. Viberti GC, Mogensen CE, Passa P, et al. St Vincent Declaration, 1994: guidelines for the prevention of diabetic renal failure. In: Mogensen CE, editor.The kidney and hypertension in diabetes mellitus. Boston: Kluwer Academic, 1994: 515-27
88. Gilbert R, Jerums G, Cooper ME. Diabetes and hypertension: prognostic and therapeutic considerations. Blood Press. In press
89. Bennett PH, Haffner S, Kasiske BL. et al. Diabetic disease recommendations. Screening and management of microalbuminuria in patients with diabetes: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995; 25: 107-12
90. Gilbert RE, Jasik M, DeLuise M, et al. Position statement diabetes and hypertension. Med J Aust 1995; 163: 372-5